Pfizer, Sangamo dose first participant in phase 3 study of Hemophilia A gene therapy treatment

This article was originally published here

AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe

The post Pfizer, Sangamo dose first participant in phase 3 study of Hemophilia A gene therapy treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply